Clinical pharmacology of the biological response modifier maleic anhydride divinyl ether copolymer (MVE-2)

Michael G. Rosenblum, Adan M. Rios, Evan M Hersh

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The anionic pyran copolymers represent a novel class of high molecular weight biological response modifiers with antitumor activity. Clinical pharmacology studies were performed on MVE-2, a polymer with an average molecular weight of 15.5 Kd. MVE-2 was analyzed in plasma and urine by HPLC. In addition, pharmacology studies were also performed using [14C] labeled MVE-2. The clearance of unlabeled MVE-2 from plasma was monophasic and the t1/2 for MVE-2 was extremely short (between 10 and 26 min). The apparent volume of distribution (Vd) varied from 12-18 l. Both the t1/2 and the Vd did not appear to be dose-dependent. The plasma clearance for [14C] labeled MVE-2 was studied in seven patients. The clearance of [14C] labeled MVE-2 fit a biphasic mathematical model. The alpha phase half-life was between 11 and 18 min while the beta phase half-life was between 70 and 85 min. Urinary excretion for either unlabeled drug or the [14C] label was between 30 and 45% of the administered dose. These studies show that, in man, the polyanionic macromolecule MVE-2 is cleared rapidly from plasma and excreted extensively in urine.

Original languageEnglish (US)
Pages (from-to)243-246
Number of pages4
JournalCancer Chemotherapy and Pharmacology
Volume18
Issue number3
DOIs
StatePublished - Dec 1986
Externally publishedYes

Fingerprint

Pyran Copolymer
Clinical Pharmacology
Immunologic Factors
Plasmas
Half-Life
Molecular Weight
Molecular weight
Urine
Macromolecules
Labels
Polymers
Theoretical Models

ASJC Scopus subject areas

  • Pharmacology
  • Oncology
  • Cancer Research

Cite this

Clinical pharmacology of the biological response modifier maleic anhydride divinyl ether copolymer (MVE-2). / Rosenblum, Michael G.; Rios, Adan M.; Hersh, Evan M.

In: Cancer Chemotherapy and Pharmacology, Vol. 18, No. 3, 12.1986, p. 243-246.

Research output: Contribution to journalArticle

@article{5205c58996614892b70de765517bea82,
title = "Clinical pharmacology of the biological response modifier maleic anhydride divinyl ether copolymer (MVE-2)",
abstract = "The anionic pyran copolymers represent a novel class of high molecular weight biological response modifiers with antitumor activity. Clinical pharmacology studies were performed on MVE-2, a polymer with an average molecular weight of 15.5 Kd. MVE-2 was analyzed in plasma and urine by HPLC. In addition, pharmacology studies were also performed using [14C] labeled MVE-2. The clearance of unlabeled MVE-2 from plasma was monophasic and the t1/2 for MVE-2 was extremely short (between 10 and 26 min). The apparent volume of distribution (Vd) varied from 12-18 l. Both the t1/2 and the Vd did not appear to be dose-dependent. The plasma clearance for [14C] labeled MVE-2 was studied in seven patients. The clearance of [14C] labeled MVE-2 fit a biphasic mathematical model. The alpha phase half-life was between 11 and 18 min while the beta phase half-life was between 70 and 85 min. Urinary excretion for either unlabeled drug or the [14C] label was between 30 and 45{\%} of the administered dose. These studies show that, in man, the polyanionic macromolecule MVE-2 is cleared rapidly from plasma and excreted extensively in urine.",
author = "Rosenblum, {Michael G.} and Rios, {Adan M.} and Hersh, {Evan M}",
year = "1986",
month = "12",
doi = "10.1007/BF00273395",
language = "English (US)",
volume = "18",
pages = "243--246",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Clinical pharmacology of the biological response modifier maleic anhydride divinyl ether copolymer (MVE-2)

AU - Rosenblum, Michael G.

AU - Rios, Adan M.

AU - Hersh, Evan M

PY - 1986/12

Y1 - 1986/12

N2 - The anionic pyran copolymers represent a novel class of high molecular weight biological response modifiers with antitumor activity. Clinical pharmacology studies were performed on MVE-2, a polymer with an average molecular weight of 15.5 Kd. MVE-2 was analyzed in plasma and urine by HPLC. In addition, pharmacology studies were also performed using [14C] labeled MVE-2. The clearance of unlabeled MVE-2 from plasma was monophasic and the t1/2 for MVE-2 was extremely short (between 10 and 26 min). The apparent volume of distribution (Vd) varied from 12-18 l. Both the t1/2 and the Vd did not appear to be dose-dependent. The plasma clearance for [14C] labeled MVE-2 was studied in seven patients. The clearance of [14C] labeled MVE-2 fit a biphasic mathematical model. The alpha phase half-life was between 11 and 18 min while the beta phase half-life was between 70 and 85 min. Urinary excretion for either unlabeled drug or the [14C] label was between 30 and 45% of the administered dose. These studies show that, in man, the polyanionic macromolecule MVE-2 is cleared rapidly from plasma and excreted extensively in urine.

AB - The anionic pyran copolymers represent a novel class of high molecular weight biological response modifiers with antitumor activity. Clinical pharmacology studies were performed on MVE-2, a polymer with an average molecular weight of 15.5 Kd. MVE-2 was analyzed in plasma and urine by HPLC. In addition, pharmacology studies were also performed using [14C] labeled MVE-2. The clearance of unlabeled MVE-2 from plasma was monophasic and the t1/2 for MVE-2 was extremely short (between 10 and 26 min). The apparent volume of distribution (Vd) varied from 12-18 l. Both the t1/2 and the Vd did not appear to be dose-dependent. The plasma clearance for [14C] labeled MVE-2 was studied in seven patients. The clearance of [14C] labeled MVE-2 fit a biphasic mathematical model. The alpha phase half-life was between 11 and 18 min while the beta phase half-life was between 70 and 85 min. Urinary excretion for either unlabeled drug or the [14C] label was between 30 and 45% of the administered dose. These studies show that, in man, the polyanionic macromolecule MVE-2 is cleared rapidly from plasma and excreted extensively in urine.

UR - http://www.scopus.com/inward/record.url?scp=0022883961&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022883961&partnerID=8YFLogxK

U2 - 10.1007/BF00273395

DO - 10.1007/BF00273395

M3 - Article

C2 - 3802379

AN - SCOPUS:0022883961

VL - 18

SP - 243

EP - 246

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 3

ER -